NCT02056600View on ClinicalTrials.gov

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy
Interventions
DRUG

gemigliptin and metformin HCl extended release

Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day

DRUG

gemigliptin/metformin HCl sustained release

Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

LG Life Sciences
All Listed Sponsors
lead

LG Life Sciences

INDUSTRY

NCT02056600 - BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone. | Biotech Hunter | Biotech Hunter